در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Women’s Health Bulletin
- نوع مقاله: Journal Article
- کلمات کلیدی: Quality of Life,Breast cancer,Lymphedema,Complex Decongestive Therapy
- چکیده:
- چکیده انگلیسی: Background: Breast cancer is one of the most common malignancies all over the world. The rate of survival of the patients with cancer has increased due to developing diverse treatment methods, as a result of which the treatment-related side effects have become the focus of attention more than before. Lymphedema related to breast cancer is one of the frequent side effects which has significantly affected the patient’s quality of life. Objectives: The purpose of this research was to assess the effect of complete or complex decongestive therapy on breast cancer-related lymphedema and the patients’ quality of life. Patients and Methods: The present study was conducted from January 2013 to January 2014 and comprised 119 patients with breast cancer, related lymphedema, who had undergone complete or complex decongestive therapy (CDT). The patients’ volume and grade of lymphedema were measured and determined before and after treatment, using the direct volumeter device to measure the lymphedema volume. To determine the quality of life, the European organization for research and treatment of cancer quality of life questionnaire (EQRTC BR-23) was completed before and after the treatment. Result: The volume of lymphedema was significantly reduced after CDT (P < 0.001). The scores of quality of life were significantly increased regarding body image (BI) (P < 0.001), future prospective (FP) (P = 0.008), sexual functioning (SF) (P = 0.006), systemic therapy side effect (STSE) (P = 0.008) and arm symptoms (AS) (P < 0.001) which was clear indication of improved quality of life. Conclusions: It is concluded that not only CDT causes reduction in lymph edema volume but also it improves the life quality of patients with breast cancer-related lymphedema
- انتشار مقاله: 11-10-1348
- نویسندگان: Negin Hadi,Esmaeel Shabaninezhad,Zahra Shabgard Shahraki,Ali Montazeri,Sedigheh Tahmasebi,Zinab Zakeri,Abdolrasoul Talei
- مشاهده
- جایگاه : پژوهشی
- مجله: Middle East Journal of Cancer
- نوع مقاله: Journal Article
- کلمات کلیدی:
- چکیده:
- چکیده انگلیسی: Background: MDM2, E-cadherin, survivin and Her2 genes are involved in the regulation of normal cell growth. However, any crucial change in their expression levels can convert a normal cell into a cancer cell. Numerous studies have identified alterations of these gene expression levels in various cancers, particularly in breast cancer. Thus, they may be used as diagnostic biomarkers. In this experiment, we aim to evaluate these gene transcripts in patients’ peripheral blood and compare the results with healthy individuals.Methods: RNA was extracted from peripheral blood cells of 52 breast cancer patients and 52 healthy volunteers. Then, cDNA was synthesized and assessed for MDM2, E-cadherin, and survivin and Her2 gene transcriptions in peripheral blood samples by quantitative real-time polymerase chain reaction.Results: There were no considerable differences in the expression of MDM2, E- cadherin, survivin and Her2 in cancer patients compared to healthy individuals. However, there were significantly correlation between E-cadherin, survivin and Her2 expression and some of the clinicopathological characteristics of patients studied. Also, survivin transcripts expression was positively correlated with Her2, E-cadherin, and MDM2 gene expressions.Conclusion: These results indicated no variations in MDM2, E-cadherin, Her2 and survivin gene expressions in patients compared to controls. We might not consider the examined biomarkers as valuable prognosis factors in primary breast cancer. However, additional research should be undertaken to assess these four genes in a larger sample size.
- انتشار مقاله: 06-07-1392
- نویسندگان: Bahareh Owrangi,Mojtaba Habibagahi,Ahmad Hosseini,Negin Fazelzadeh Haghighi,Mohsen Mardani,Abdolrasoul Talei,Abbas Ghaderi,Mansooreh Jaberipour
- مشاهده
- جایگاه : پژوهشی
- مجله: Iranian Journal of Medical Sciences
- نوع مقاله: Journal Article
- کلمات کلیدی: Prognosis,Survival,Carcinoma,Breast,Medullary,Ductal
- چکیده:
- چکیده انگلیسی: Background: Medullary breast carcinoma (MBC) is a unique histological subtype of breast cancer. The present study aimed to evaluate the classic and non-classic characteristics of MBC and its differences with IDC. The present review study incorporates 22 years of practical experience from a breast disease research center-based series of cases.Methods: Retrospectively, the medical records of 3,246 patients were reviewed in the Breast Disease Research Center, Shiraz University of Medical Science (Shiraz, Iran), from December 1993 to December 2015. The tumor size, lymph node metastasis, pathologic stage, nuclear and histological grade, hormonal receptor status, recurrence, disease-free, and overall survival were reviewed. Differences between medullary breast carcinoma and invasive ductal carcinoma were analyzed statistically using the Chi-square, Fischer, independent-sample t test, and Kaplan-Meier analysis (SPSS version 19.0). P
- انتشار مقاله: 22-10-1395
- نویسندگان: Vahid Zangouri,Majid Akrami,Sedigheh Tahmasebi,Abdolrasoul Talei,Ali Ghaeini Hesarooeih,Sara Hosseini
- مشاهده
- جایگاه : پژوهشی
- مجله: Iranian Journal of Immunology
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,NK cells,lymph nodes,Invariant-NKT Cells,NKT Cells
- چکیده:
- چکیده انگلیسی: Background: NK (natural killer) and NKT (natural killer T) cells, as components of innate immune system, play a crucial role in tumor progression and dissemination. Objective: To investigate the percentages of NK cells, NKT cells, iNKT (invariant natural killer T) cells, total T lymphocytes as well as activated T lymphocytes, in tumor draining lymph nodes (TDLNs) of patients with breast cancer (BC) and their association with different clinic-pathological features of the patients. Methods: Axillary lymph nodes were obtained from 30 Iranian women with breast cancer. After routine pathological evaluations, mononuclear cells were separated from their lymph nodes and incubated with appropriate fluorochrome conjugated monoclonal antibodies specific for CD3, HLA-DR, CD16/56, and Vα24Jα18-TCR. Data were collected on a four-color flow cytometer and analyzed by CellQuest software. Results: The mean percentages of NK (CD3-CD16/56+), NKT (CD3+CD16/56+) and iNKT (Vα24Jα18-TCR+) cells in TDLNs mononuclear cells of BC patients were 2.04%, 2.44% and 0.1%, respectively. A significant decrease in the percentages of NK and iNKT subsets in patients with grade I was observed compared to grade III (p=0.03 and p=0.01, respectively). Moreover, NK cells were increased in patients with grade III of BC compared to grade II (p= 0.003). Conclusion: The increase in the percentage of NK and iNKT cells in TDLNs of patients with higher grade of BC might suggest a suppressive phenotype for these cells in breast cancer, which merit more functional investigation.
- انتشار مقاله: 07-05-1398
- نویسندگان: Somayeh Rezaeifard,Akbar Safaei,Abdolrasoul Talei,Zahra Faghih,Nasrollah Erfani
- مشاهده
- جایگاه : پژوهشی
- مجله: Iranian Journal of Immunology
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,Serum,Her-2,Iranian
- چکیده:
- چکیده انگلیسی: Background: A soluble form of HER-2/neu extracellular domain (sHER-2) is reported to be released in the sera of metastatic breast cancer patients.
Objective: To measure the level of sHER-2 in sera of 115 breast cancer patients.
Methods: Serial samples of 27 patients with metastasis, 18 non-metastatic patients, 15 patients in stage 0/I and 14 patients with accompanying benign breast disease were also included in this study.
Results: No significant difference was observed between sHER- 2 level in the pre-operative sera of breast cancer patients and that of healthy individuals. Only 8 out of 27 patients whom later developed metastasis showed elevated levels of sHER-2 in their first serum sample. However, a trend of increase in the level of sHER-2 was observed in 14 (51.8%) of 27 metastatic sera before clinical diagnosis of the metastasis. A significant association between sHER-2 positive status and vascular invasion of the tumor was observed (P = 0.02). In addition, significant correlation of sHER-2 level with CEA (highest r = 0.74) and CA 15.3 (highest r = 0.74) tumor marker levels in the serial sera were observed. The mean time from sHER-2 positivity to tumor metastasis was calculated to be 98 days (range = 29-174).
Conclusion: Our results indicate that a relatively high percentage of Iranian patients with breast cancer show an elevated level of sHER-2 in their sera before clinical diagnosis of the tumor metastasis. Therefore, measuring the level of this oncoprotein, not only helps physicians in monitoring the patients during HERCEPTINTM therapy, but also can be helpful in choosing more aggressive treatments at the early satges of tumor metastasis.- انتشار مقاله: 16-05-1395
- نویسندگان: Mehrnoosh Doroudchi,Abdolrasoul Talei,Helmout Modjtahedi,Alamtaj Samsami Dehaghani,Abdol Mohammad Pezeshki,Hilary Thomas,Abbas Ghaderi
- مشاهده
- جایگاه : پژوهشی
- مجله: Iranian Journal of Immunology
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,Progesterone Receptor,IL-10,Polymorphism
- چکیده:
- چکیده انگلیسی: Background: IL-10 is an anti-inflammatory cytokine which is involved in tumorigenesis. Over production of IL-10 and elevated number of IL-10 generating mononuclear cells in breast tumor tissue has already been shown.
Objective: To determine the association of IL-10 promoter polymorphisms with increased risk of breast cancer and its association with breast cancer prognostic factors.
Methods: Peripheral blood samples from 275 female breast cancer patients and 320 cancer free controls were used to detect three single nucleotide polymorphisms in IL-10 promoter region ( -1082, -819, -592 ) by PCR method.
Results: The frequency of genotypes and alleles of three mentioned regions of IL-10 promoter and their haplotypes (GCC, ATA, and ACC) showed no statistically significant difference between patients and controls. In the case of prognostic factors, progesterone receptor (PR) status exhibited significant relation with -1082 genotypes (P=0.03) and haplotypes (P=0.02). -1082 AA genotype was associated with negative PR expression whereas AG and GG genotypes of this site were positively associated with PR expression. Similarly GCC haplotype correlated with positive PR expression and ATA and ACC with negative PR expression.
Conclusion: The data of this study showed that IL-10 promoter gene polymorphisms may not be considered as one of the risk factors for breast cancer in Iranian patients.- انتشار مقاله: 16-05-1395
- نویسندگان: Hossein Abdolrahim-Zadeh,Niloufar Hakkakian,Reza Asadollahi,Behrouz Gharesifard,Jamal Sarvari,Eskandar Kamali-Sarvestani,Abdolrasoul Talei
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Triple-negative breast cancer,Her2/neu,hormone receptor,Basal-like tumor
- چکیده:
- چکیده انگلیسی: Background: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer (BC), and its diagnosis is associated with negative expression of hormone receptors and HER2/neu. It consists of 10-20% of all BCs diagnosed. Methods and materials: This study focuses on three groups with different pathology: group one showed complete triple-negative HER2 expression with IHC of BC; groups two and three included patients with ER-, PR-, and HER21+, and ER-, PR-, and HER22+ with a negative FISH test. These three groups were compared from the point of prognosis, which consisted of tumor size, patients’ age, lymphatic, vascular and perineural invasion, organ metastasis, number of lymph nodes involvement, and the survival rate. Results: A total of 459 TNBC patients were enrolled, of which 268 were placed in the HER20 group, 146 in the HER21+ group, and 45 in the HER22+ group. Distant metastasis and recurrence rate were more common in HER20 patients, but bone metastasis was more common in patients with low HER2 expression. All patients with HER20 had a smaller tumor size at the time of BC diagnosis in comparison to patients in the low HER2 expression group. Patients with HER22+ had less lymphatic and vascular invasion as well as axillary lymph nodes involvement, but larger tumor size at presentation, resulting in a lower rate of recurrence and higher overall survival. Conclusion: The findings revealed that patients with HER22+ had better outcome in comparison to the patients with HER20 and HER21+. Furthermore, the results showed that many patients with HER22+ expression were not basal-like and had good prognosis amongst TNBC patients.
- انتشار مقاله: 25-02-1399
- نویسندگان: Mehdi Dehghani,Pedram Keshavarz,Abdolrasoul Talei,Majid Akrami,Sedighe Tahmasebi,Akbar Safaie,Maryam Ghanbari
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,Cell line establishment,Triple-negative
- چکیده:
- چکیده انگلیسی: Breast cancer is the most common malignancy and the leading cause of cancer-related death among women
worldwide. The underlying mechanisms for breast cancer development, especially in young women, are not completely
understood. Although there are several experimental models to understand the biology of breast cancer such as
immortalized cell lines, many of these cell lines have been in culture for decades and most of them have been derived
from Caucasians or African-Americans. So, it is required to establish a new cell line derived from primary tumors and
Asian women. In this study Pari-Institute for Cancer Research (Pari-ICR) was derived from the primary breast tumor
of a 36-years old patient with invasive ductal carcinoma. We characterized the cell line by examining morphology,
expression of different markers, and functional profile. Immunocytochemistry showed that this cell line does not express
estrogen and progesterone receptors as well as human epidermal growth factor receptor 2 (HER2). Pari-ICR cell line
expresses high levels of Vimentin, Ezrin, and S100 but does not express EpCAM, Cytokeratin19, Pan-cytokeratin,
Nestin, and Desmin. Its doubling time of Pari-ICR was about 22h and was able to grow as colonies in soft agar. It
displayed a higher ability of migration and invasion in comparison with MCF-7 cell line. This breast cancer cell line
can serve as a model for understanding the molecular mechanisms of breast carcinogenesis. Moreover, it can be used
as an appropriate resource to find novel biomarkers or assess new drugs.- انتشار مقاله: 10-05-1397
- نویسندگان: Farzaneh Ghaderi,Fereshteh Mehdipour,Ahmad Hosseini,Abdolrasoul Talei,Abbas Ghaderi
- مشاهده